Skip to content
Physician Case Review Consult

When an AI Tool Is Used Outside Its Intended Population

An AI tool validated on adults may behave differently for a child or a pregnant patient. Intended use and local validation records show whether anyone checked.

Consider a hypothetical. A 15-year-old with fever and abdominal pain is seen in a general emergency department that treats adults and children. The department uses a sepsis risk tool that was developed and validated on adult patients. Teenagers have different normal ranges for heart rate and blood pressure, and the tool scores her as low risk. She is discharged and returns the next day in septic shock.

AI tools are built and tested on particular patients. When they are used on patients who differ from those, their performance can change in ways nobody has measured. Children are the clearest example, because their physiology changes with age and size, but the same issue arises with pregnant patients, older adults, patients with rare conditions, and populations underrepresented in a tool’s training data.

Intended use is a fact, and it is usually written down. Most AI tools come with a statement of what they are for and for whom. For tools regulated by the FDA as medical devices, the labeling states the intended use and population. Many clinical AI tools are not regulated devices; FDA’s clinical decision support guidance explains how some software aimed at clinicians falls outside device regulation if it meets four criteria. For those tools, the intended population appears in vendor documentation, model fact sheets, contracts, and the hospital’s own approval records. Either way, there is usually a document that says who the tool was meant for.

What the guidance expects. The Joint Commission and the Coalition for Health AI (CHAI) 2025 guidance on responsible AI use is voluntary, but its element on risk and bias assessment speaks directly to this problem. It recommends asking vendors how a tool was tested and for which populations, testing tools on local data for the populations an organization actually serves, and continuing to monitor for performance gaps after go-live. Its own illustration is a tool built on younger, healthier patients that performs worse in older ones. CHAI’s risk categorization approach also asks whether some patient groups face greater risk from a tool’s errors, and treats that as a reason for closer review before deployment.

How it happens in practice. Scope problems are rarely a deliberate decision to use a tool on the wrong patient. More often:

  • The tool runs automatically on every patient in a unit, and no one configured it to exclude patients outside its validated range.
  • A unit that mostly treats adults also sees adolescents or young children, and the tool was approved with the majority in mind.
  • The tool was validated elsewhere, and the hospital accepted that validation without checking how the tool performed on its own patients.
  • The clinician did not know the tool’s limits, because training did not cover them.

Records to request.

  • The vendor’s statement of intended use and population, and any model fact sheet or validation summary.
  • The hospital’s approval record for the tool, including the populations and units it was approved for.
  • Local validation results, ideally broken down by age group or other relevant subgroups.
  • Configuration showing which patients the tool ran on, and any age or unit exclusions.
  • Training materials given to clinicians about the tool’s limits.
  • Monitoring reports after deployment, and any reported concerns about performance in particular groups.

Reading it fairly. Using a tool outside its validated population is not automatically unreasonable. Clinicians use many tools and medications outside their formal labeling, sometimes for good reasons, and a risk score is only one input among many. A clinician who examined the teenager, recognized she was sick, and acted on that judgment is not bound by a low score. The fair questions are narrower. Did the organization know the tool’s limits? Did it decide, on purpose, how the tool would be used for patients outside them? Did the clinician rely on the score in a way the tool was never designed to support?

For pediatric cases in particular, these questions deserve early attention. Children’s normal ranges vary by age, many adult-derived tools handle that poorly, and a mixed adult and pediatric setting is exactly where a tool’s blind spot can go unnoticed. The intended use statement, the approval record, and the local validation data will show whether anyone looked.

Sources

  • Joint Commission and Coalition for Health AI. The Responsible Use of AI in Healthcare (RUAIH). 2025. jointcommission.org
  • Coalition for Health AI. Risk Categorization Tool, version 3. chai.org
  • US Food and Drug Administration. Clinical Decision Support Software: Guidance for Industry and FDA Staff. fda.gov

The scenario above is hypothetical. Disclosure: Dr. Bansal is Chief Medical Officer of Diagnose Data, Inc., a healthcare technology company. This article does not describe or endorse any product.

This article is educational and does not constitute legal advice. Safety classifications and voluntary guidance describe reporting and improvement frameworks, not a legal standard of care or any outcome. Sources are listed at the end of the article.